



Working Group 3

Workshop on technology commercialization and IP utilization in venom research

“So we got a patent, what now?”

Venue: Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czechia; Vídeňská 1083, Building F, Lecture room No. 0.195

Dates: 7. – 8.3. 2024

PROGRAM

Thursday 7.03. 2024

12:00 – 13:00 registration

13:00 – 14:00 What does your start-up need to be ready for investors? Process of evaluating and supporting startups before i&i Biotech Fund / any fund decides to invest.

Dr. Jiří Moos, CEO at i&i Prague, **Karel Kubias**, MBA, Partner at i&i Bio fund

- What to expect from early-stage investors and where to look for them;
- evaluation criteria for Bio and MedTech Funds;
- key investment criteria of i&i Biotech Fund.
- Commercialization strategy troubleshooting - what to keep in mind when considering commercialization.
- Bonus topic: toxins as reagents from the i&i Prague point of view - what are the musts to enter a RUO/diagnostics project development with i&i Prague.

The workshop block is interactive, discussion is open.

14:00 – 15:30 Pitch of technologies from the EUVEN members

i&i Prague, i&i Bio, EUVEN COST participants

- Pitch of selected technologies.

The workshop block is interactive, discussion is open.



15:30 – 16:00 Coffee break

16:00 – 17:00 Pentapharm AG, the largest producer and supplier of purified and synthetic snake venom enzymes for cosmetic industry and medical applications.

Dr. Kally Wong, Pentapharm Business Head Pharma & Diagnostic

- Pentapharm company introduction.
- Trends in industrial applications of venoms according to Pentapharm,
- in-licensing interests, pipeline, development, cooperation potential for academic CRO activities and publicfund projects.

The lecturer workshop block is interactive, discussion is open.

17:00 – 18:00 Unorthodox antidote – toxin development and applications in the army.

PharmDr. Lukáš Górecki, Ph.D., Toxicology and military pharmacology department, University of Defense

- Synthetic chemicals, antidotes, warfare toxins. Toxicology and medical development in the military field – what we do, where can we help in applications (preclinical development, trials).
- Case study of warfare toxin antidote development and commercialization, history and current situation of clinical trials in the Army. Is it still possible to get API to market without a strong pharma partner?

The workshop block is interactive, discussion is open.

18:00 – 22:00 networking activities

Workshop In Cooperation With:





Friday 8.03. 2024

9:00 - 10:00 Getting patent to application – experience from the academia.

Ing. Martin Smekal, Head of Central technology transfer office, AS CR

- Academics and general approach to applications – pros and cons, trends and pits.
- Bottlenecks of startups - what kills the IP and startup, what to prevent, how to be prepared, discussion on our recent startup cases.
- What to expect from a startup in terms of money making.

The workshop block is interactive, discussion is open.

10:00 – 10:30 EUVEN workshop further steps.

Michal Schmoranz, Technology transfer office Institute of Molecular Genetics AS CR

- Current EUVEN IP, background and foreground policies, MTA, NDA, IPR, transforming the consortia, domicile and responsible research, licensing technology co-owned by the consortia partners.
- Commercialization vs. utilization vs. IP protection

10:30 – 11:00 EUVEN take home message.

Prof. Gregor Anderluh, EUVEN Management committee, Director of National Institute of Chemistry, Slovenia

11:00 – 11:45 CZ-OPENSREEN visit of a state-of-the-art infrastructure for chemical biology and genetics offering open access to potential users from Czechia as well as from abroad.

12:00 – 12:40 The Czech Centre for Phenogenomics visit of a large research infrastructure combining genetic engineering capabilities, advanced phenotyping and imaging modalities, SPF animal housing and husbandry, cryopreservation, and archiving.